Opinion|Videos|December 23, 2024

Infection Prevention and Leveraging EHR for Bispecific Therapy Management

Key Takeaways

  • Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
  • Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
SHOW MORE

Panelists discuss insights on infection prevention protocols and electronic health record (EHR)–based toxicity management strategies for patients receiving bispecific antibody therapies in relapsed/refractory multiple myeloma (RRMM).

Video content above is prompted by the following

  • What best practices can you share regarding preventing infection in patients receiving bispecific therapies in RRMM?
  • How has your institution leveraged the electronic health record to assist with standardization and management of toxicities seen with bispecific therapies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe

Related to this article

Could Linvoseltamab Change When We Treat High-Risk Smoldering Myeloma?
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.